Pancreatic cancer future or investigational therapies: Difference between revisions

	Pancreatic cancer Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Pancreatic Cancer from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Staging
Diagnostic study of choice
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Pancreatic cancer future or investigational therapies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Pancreatic cancer future or investigational therapies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Pancreatic cancer future or investigational therapies
CDC on Pancreatic cancer future or investigational therapies
Pancreatic cancer future or investigational therapies in the news
Blogs on Pancreatic cancer future or investigational therapies
Directions to Hospitals Treating Pancreatic cancer
Risk calculators and risk factors for Pancreatic cancer future or investigational therapies

Revision as of 18:12, 13 November 2017

@@ Line 2: / Line 2: @@
 {{Pancreatic cancer}}
-NEW TREATMENTS
- Irinotecan in an encapsulated form inside a nanoliposome is being used in advanced pancreatic cancer patients who have been earlier been treated using gemcitabine-based chemotherapy. <ref name="pmid27140876">{{cite journal |vauthors=Chiang NJ, Chang JY, Shan YS, Chen LT |title=Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer |journal=Expert Opin Pharmacother |volume=17 |issue=10 |pages=1413–20 |year=2016 |pmid=27140876 |doi=10.1080/14656566.2016.1183646 |url=}}</ref>
-Liposomal Irinotecan is used along with leucovorin and fluorouracil.<ref name="pmid26615328">{{cite journal |vauthors=Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT |title=Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial |journal=Lancet |volume=387 |issue=10018 |pages=545–57 |year=2016 |pmid=26615328 |doi=10.1016/S0140-6736(15)00986-1 |url=}}</ref>